Maxim lowered the firm’s price target on SeaStar Medical (ICU) to $6 from $10 and keeps a Buy rating on the shares. The firm cites the company having announced the publication of positive early post-approval clinical experience from the use of the QUELIMMUNE therapy in the peer-reviewed journal of Pediatric Nephrology, though its price target reflects SeaStar’s share dilution, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICU: